Halladay Benjamin 4

What Happened

• Benjamin Halladay, Chief Financial Officer of Esperion Therapeutics (ESPR), reported a sale of 10,773 shares on 2026-06-17. The shares were disposed at $3.15 each for a total value of $33,989. The transaction is reported as an open-market or private sale (code S).

Key Details

• Transaction date: 2026-06-17; Price: $3.15 per share; Total proceeds: $33,989.
• Shares owned after the transaction: not disclosed in the provided filing summary.
• Footnote: F1 — shares were sold to satisfy tax obligations on vested restricted stock units (RSUs).
• Filing date/accession: reported on Form 4 filed 2026-06-18; appears to be timely (filed the next day).

Context

• This sale was to cover tax withholding on vested RSUs, a common administrative reason for insider sales and not necessarily a signal of management’s view on the company’s prospects. Sales to satisfy taxes are routine and differ from discretionary, investment-motivated purchases.